Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Targeting Bacterial Cell Division: A Binding Site-Centered Approach to the Most Promising Inhibitors of the Essential Protein FtsZ.

Casiraghi A, Suigo L, Valoti E, Straniero V.

Antibiotics (Basel). 2020 Feb 7;9(2). pii: E69. doi: 10.3390/antibiotics9020069. Review.

2.

Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.

Faustini G, Longhena F, Bruno A, Bono F, Grigoletto J, La Via L, Barbon A, Casiraghi A, Straniero V, Valoti E, Costantino G, Benfenati F, Missale C, Pizzi M, Spillantini MG, Bellucci A.

Neurobiol Dis. 2020 Feb 4;138:104789. doi: 10.1016/j.nbd.2020.104789. [Epub ahead of print]

3.

Benzodioxane-Benzamides as Antibacterial Agents: Computational and SAR Studies to Evaluate the Influence of the 7-Substitution in FtsZ Interaction.

Straniero V, Sebastián-Pérez V, Hrast M, Zanotto C, Casiraghi A, Suigo L, Zdovc I, Radaelli A, De Giuli Morghen C, Valoti E.

ChemMedChem. 2020 Jan 17;15(2):195-209. doi: 10.1002/cmdc.201900537. Epub 2019 Dec 11.

PMID:
31750973
4.

More about Factor H Autoantibodies in Membranous Nephropathy.

Valoti E, Noris M, Remuzzi G.

N Engl J Med. 2019 Oct 17;381(16):1590-1592. doi: 10.1056/NEJMc1905608. No abstract available.

PMID:
31618548
5.

Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes.

Valoti E, Noris M, Perna A, Rurali E, Gherardi G, Breno M, Parvanova Ilieva A, Petrov Iliev I, Bossi A, Trevisan R, Dodesini AR, Ferrari S, Stucchi N, Benigni A, Remuzzi G, Ruggenenti P.

Front Genet. 2019 Jul 26;10:681. doi: 10.3389/fgene.2019.00681. eCollection 2019.

6.

Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS.

Valoti E, Alberti M, Iatropoulos P, Piras R, Mele C, Breno M, Cremaschi A, Bresin E, Donadelli R, Alizzi S, Amoroso A, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2019 May 1;10:853. doi: 10.3389/fimmu.2019.00853. eCollection 2019.

7.

Hemolytic Uremic Syndrome in an Infant with Primary Hyperoxaluria Type II: An Unreported Clinical Association.

Valoti E, Alberti M, Carrara C, Breno M, Yilmaz Keskin E, Bresin E, Cuccarolo P, Açikgöz Y, Benigni A, Noris M, Remuzzi G, Mele C.

Nephron. 2019;142(3):264-270. doi: 10.1159/000497823. Epub 2019 Mar 19.

PMID:
30889567
8.

An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome.

Galbusera M, Noris M, Gastoldi S, Bresin E, Mele C, Breno M, Cuccarolo P, Alberti M, Valoti E, Piras R, Donadelli R, Vivarelli M, Murer L, Pecoraro C, Ferrari E, Perna A, Benigni A, Portalupi V, Remuzzi G.

Am J Kidney Dis. 2019 Jul;74(1):56-72. doi: 10.1053/j.ajkd.2018.11.012. Epub 2019 Mar 7.

PMID:
30851964
9.

Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.

Donadelli R, Pulieri P, Piras R, Iatropoulos P, Valoti E, Benigni A, Remuzzi G, Noris M.

Front Immunol. 2018 Oct 15;9:2329. doi: 10.3389/fimmu.2018.02329. eCollection 2018.

10.

How Reaction Conditions May Influence the Regioselectivity in the Synthesis of 2,3-Dihydro-1,4-benzoxathiine Derivatives.

Casiraghi A, Valoti E, Suigo L, Artasensi A, Sorvillo E, Straniero V.

J Org Chem. 2018 Nov 2;83(21):13217-13227. doi: 10.1021/acs.joc.8b02012. Epub 2018 Oct 11.

PMID:
30265535
11.

Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers.

Volpi N, Mantovani V, Galeotti F, Bianchi D, Straniero V, Valoti E, Miraglia N.

Clin Pharmacol Drug Dev. 2019 Apr;8(3):336-345. doi: 10.1002/cpdd.587. Epub 2018 Jul 24.

PMID:
30040242
12.

Stressed degradation studies of domiphen bromide by LC-ESI-MS/MS identify a novel promising antimicrobial agent.

Fumagalli L, Regazzoni LG, Straniero V, Valoti E, Aldini G, Vistoli G, Carini M, Picozzi C.

J Pharm Biomed Anal. 2018 Sep 10;159:224-228. doi: 10.1016/j.jpba.2018.06.055. Epub 2018 Jun 30.

PMID:
29990889
13.

How do reaction conditions affect the enantiopure synthesis of 2-substituted-1,4-benzodioxane derivatives?

Straniero V, Casiraghi A, Fumagalli L, Valoti E.

Chirality. 2018 Jul;30(7):943-950. doi: 10.1002/chir.22968. Epub 2018 May 12.

PMID:
29752740
14.

Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, Mele C, Bresin E, Gamba S, Alberti M, Breno M, Perna A, Bettoni S, Sabadini E, Murer L, Vivarelli M, Noris M, Remuzzi G; Registry of Membranoproliferative Glomerulonephritis/C3 Glomerulopathy; Nastasi.

J Am Soc Nephrol. 2018 Jan;29(1):283-294. doi: 10.1681/ASN.2017030258. Epub 2017 Oct 13.

15.

2,6-Difluorobenzamide Inhibitors of Bacterial Cell Division Protein FtsZ: Design, Synthesis, and Structure-Activity Relationships.

Straniero V, Zanotto C, Straniero L, Casiraghi A, Duga S, Radaelli A, De Giuli Morghen C, Valoti E.

ChemMedChem. 2017 Aug 22;12(16):1303-1318. doi: 10.1002/cmdc.201700201. Epub 2017 Jul 11.

PMID:
28586174
16.

The Feasibility of a Completely Automated Total IV Anesthesia Drug Delivery System for Cardiac Surgery.

Zaouter C, Hemmerling TM, Lanchon R, Valoti E, Remy A, Leuillet S, Ouattara A.

Anesth Analg. 2016 Oct;123(4):885-93. doi: 10.1213/ANE.0000000000001152.

PMID:
27644009
17.

3-(Benzodioxan-2-ylmethoxy)-2,6-difluorobenzamides bearing hydrophobic substituents at the 7-position of the benzodioxane nucleus potently inhibit methicillin-resistant Sa and Mtb cell division.

Straniero V, Pallavicini M, Chiodini G, Zanotto C, Volontè L, Radaelli A, Bolchi C, Fumagalli L, Sanguinetti M, Menchinelli G, Delogu G, Battah B, De Giuli Morghen C, Valoti E.

Eur J Med Chem. 2016 Sep 14;120:227-43. doi: 10.1016/j.ejmech.2016.03.068. Epub 2016 Mar 28.

PMID:
27191617
18.
19.

Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome.

Iatropoulos P, Noris M, Mele C, Piras R, Valoti E, Bresin E, Curreri M, Mondo E, Zito A, Gamba S, Bettoni S, Murer L, Fremeaux-Bacchi V, Vivarelli M, Emma F, Daina E, Remuzzi G.

Mol Immunol. 2016 Mar;71:131-142. doi: 10.1016/j.molimm.2016.01.010. Epub 2016 Feb 16.

PMID:
26895476
20.

Behavioural and pharmacological characterization of a novel cannabinomimetic adamantane-derived indole, APICA, and considerations on the possible misuse as a psychotropic spice abuse, in C57bl/6J mice.

Cannizzaro C, Malta G, Argo A, Brancato A, Roda G, Casagni E, Fumagalli L, Valoti E, Froldi R, Procaccianti P, Gambaro V.

Forensic Sci Int. 2016 Aug;265:6-12. doi: 10.1016/j.forsciint.2015.12.035. Epub 2016 Jan 6.

21.

A selective alpha1D-adrenoreceptor antagonist inhibits human prostate cancer cell proliferation and motility "in vitro".

Colciago A, Mornati O, Ferri N, Castelnovo LF, Fumagalli L, Bolchi C, Pallavicini M, Valoti E, Negri-Cesi P.

Pharmacol Res. 2016 Jan;103:215-26. doi: 10.1016/j.phrs.2015.11.017. Epub 2015 Nov 24.

22.

Association of CFHR1 homozygous deletion with acute myelogenous leukemia in the European population.

Fratelli M, Bolis M, Kurosaki M, Dori M, Guarnaccia V, Spinelli O, Alberti M, Valoti E, Pileggi S, Noris M, Remuzzi G, Rambaldi A, Terao M, Garattini E.

Leuk Lymphoma. 2016 May;57(5):1234-7. doi: 10.3109/10428194.2015.1082180. Epub 2016 Mar 2. No abstract available.

PMID:
26317246
23.

Chemistry and Pharmacology of a Series of Unichiral Analogues of 2-(2-Pyrrolidinyl)-1,4-benzodioxane, Prolinol Phenyl Ether, and Prolinol 3-Pyridyl Ether Designed as α4β2-Nicotinic Acetylcholine Receptor Agonists.

Bolchi C, Valoti E, Gotti C, Fasoli F, Ruggeri P, Fumagalli L, Binda M, Mucchietto V, Sciaccaluga M, Budriesi R, Fucile S, Pallavicini M.

J Med Chem. 2015 Aug 27;58(16):6665-77. doi: 10.1021/acs.jmedchem.5b00904. Epub 2015 Aug 18.

24.

Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome.

Mele C, Lemaire M, Iatropoulos P, Piras R, Bresin E, Bettoni S, Bick D, Helbling D, Veith R, Valoti E, Donadelli R, Murer L, Neunhäuserer M, Breno M, Frémeaux-Bacchi V, Lifton R, Remuzzi G, Noris M.

Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1011-9. doi: 10.2215/CJN.08520814. Epub 2015 Apr 8.

25.

Mapping interactions between complement C3 and regulators using mutations in atypical hemolytic uremic syndrome.

Schramm EC, Roumenina LT, Rybkine T, Chauvet S, Vieira-Martins P, Hue C, Maga T, Valoti E, Wilson V, Jokiranta S, Smith RJ, Noris M, Goodship T, Atkinson JP, Fremeaux-Bacchi V.

Blood. 2015 Apr 9;125(15):2359-69. doi: 10.1182/blood-2014-10-609073. Epub 2015 Jan 21.

26.

Benzodioxane-benzamides as new bacterial cell division inhibitors.

Chiodini G, Pallavicini M, Zanotto C, Bissa M, Radaelli A, Straniero V, Bolchi C, Fumagalli L, Ruggeri P, De Giuli Morghen C, Valoti E.

Eur J Med Chem. 2015 Jan 7;89:252-65. doi: 10.1016/j.ejmech.2014.09.100. Epub 2014 Oct 18.

PMID:
25462242
27.

Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Noris M, Galbusera M, Gastoldi S, Macor P, Banterla F, Bresin E, Tripodo C, Bettoni S, Donadelli R, Valoti E, Tedesco F, Amore A, Coppo R, Ruggenenti P, Gotti E, Remuzzi G.

Blood. 2014 Sep 11;124(11):1715-26. doi: 10.1182/blood-2014-02-558296. Epub 2014 Jul 18.

28.

From 2-aminomethyl-1,4-benzodioxane enantiomers to unichiral 2-cyano- and 2-carbonyl-substituted benzodioxanes via dichloroamine.

Bolchi C, Valoti E, Straniero V, Ruggeri P, Pallavicini M.

J Org Chem. 2014 Jul 18;79(14):6732-7. doi: 10.1021/jo500964y. Epub 2014 Jun 26.

PMID:
24945589
29.

A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.

Valoti E, Alberti M, Tortajada A, Garcia-Fernandez J, Gastoldi S, Besso L, Bresin E, Remuzzi G, Rodriguez de Cordoba S, Noris M.

J Am Soc Nephrol. 2015 Jan;26(1):209-19. doi: 10.1681/ASN.2013121339. Epub 2014 Jun 5.

30.

Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds.

Straniero V, Pallavicini M, Chiodini G, Ruggeri P, Fumagalli L, Bolchi C, Corsini A, Ferri N, Ricci C, Valoti E.

Bioorg Med Chem Lett. 2014 Jul 1;24(13):2924-7. doi: 10.1016/j.bmcl.2014.04.078. Epub 2014 Apr 30.

PMID:
24821376
31.

Characterization of in vitro metabolites of JWH-018, JWH-073 and their 4-methyl derivatives, markers of the abuse of these synthetic cannabinoids.

Gambaro V, Arnoldi S, Bellucci S, Casagni E, Dell'Acqua L, Fumagalli L, Pallavicini M, Roda G, Rusconi C, Valoti E.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Apr 15;957:68-76. doi: 10.1016/j.jchromb.2014.03.001. Epub 2014 Mar 12.

PMID:
24657413
32.

Design, synthesis and binding affinity of acetylcholine carbamoyl analogues.

Bolchi C, Valoti E, Binda M, Fasoli F, Ferrara R, Fumagalli L, Gotti C, Matucci R, Vistoli G, Pallavicini M.

Bioorg Med Chem Lett. 2013 Dec 1;23(23):6481-5. doi: 10.1016/j.bmcl.2013.09.023. Epub 2013 Sep 18.

PMID:
24128660
33.

6-methoxy-7-benzofuranoxy and 6-methoxy-7-indolyloxy analogues of 2-[2-(2,6-Dimethoxyphenoxy)ethyl]aminomethyl-1,4-benzodioxane (WB4101):1 discovery of a potent and selective α1D-adrenoceptor antagonist.

Fumagalli L, Pallavicini M, Budriesi R, Bolchi C, Canovi M, Chiarini A, Chiodini G, Gobbi M, Laurino P, Micucci M, Straniero V, Valoti E.

J Med Chem. 2013 Aug 22;56(16):6402-12. doi: 10.1021/jm400867d. Epub 2013 Jul 31.

PMID:
23902232
34.

Exploring the space of histidine containing dipeptides in search of novel efficient RCS sequestering agents.

Vistoli G, De Maddis D, Straniero V, Pedretti A, Pallavicini M, Valoti E, Carini M, Testa B, Aldini G.

Eur J Med Chem. 2013 Aug;66:153-60. doi: 10.1016/j.ejmech.2013.05.009. Epub 2013 May 30.

PMID:
23792353
35.

Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature.

Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C.

Nephrol Dial Transplant. 2013 Sep;28(9):2246-59. doi: 10.1093/ndt/gft220. Epub 2013 Jun 19. Review.

PMID:
23787552
36.

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.

Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M.

Am J Transplant. 2013 Aug;13(8):2201-6. doi: 10.1111/ajt.12297. Epub 2013 Jun 3.

37.

Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M; European Working Party on Complement Genetics in Renal Diseases.

J Am Soc Nephrol. 2013 Feb;24(3):475-86. doi: 10.1681/ASN.2012090884. Epub 2013 Feb 21.

38.

Affinity and activity profiling of unichiral 8-substituted 1,4-benzodioxane analogues of WB4101 reveals a potent and selective α1B-adrenoceptor antagonist.

Fumagalli L, Pallavicini M, Budriesi R, Gobbi M, Straniero V, Zagami M, Chiodini G, Bolchi C, Chiarini A, Micucci M, Valoti E.

Eur J Med Chem. 2012 Dec;58:184-91. doi: 10.1016/j.ejmech.2012.09.049. Epub 2012 Oct 16.

PMID:
23124215
39.

Identification of 1-butyl-3-(1-(4-methyl)naphtoyl)indole detected for the first time in "herbal high" products on the Italian market.

Valoti E, Casagni E, Dell'Acqua L, Pallavicini M, Roda G, Rusconi C, Straniero V, Gambaro V.

Forensic Sci Int. 2012 Nov 30;223(1-3):e42-6. doi: 10.1016/j.forsciint.2012.08.009. Epub 2012 Aug 29.

PMID:
22939184
40.

Posttransplant recurrence of atypical hemolytic uremic syndrome.

Valoti E, Alberti M, Noris M.

J Nephrol. 2012 Nov-Dec;25(6):911-7. doi: 10.5301/jn.5000146. Review.

PMID:
22760880
41.

Predicting the physicochemical profile of diastereoisomeric histidine-containing dipeptides by property space analysis.

Vistoli G, Straniero V, Pedretti A, Fumagalli L, Bolchi C, Pallavicini M, Valoti E, Testa B.

Chirality. 2012 Jul;24(7):566-76. doi: 10.1002/chir.22056. Epub 2012 May 8.

PMID:
22566161
42.

Unichiral 2-(2'-pyrrolidinyl)-1,4-benzodioxanes: the 2R,2'S diastereomer of the N-methyl-7-hydroxy analogue is a potent α4β2- and α6β2-nicotinic acetylcholine receptor partial agonist.

Bolchi C, Gotti C, Binda M, Fumagalli L, Pucci L, Pistillo F, Vistoli G, Valoti E, Pallavicini M.

J Med Chem. 2011 Nov 10;54(21):7588-601. doi: 10.1021/jm200937t. Epub 2011 Oct 11.

PMID:
21942635
43.

Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.

Bolchi C, Pallavicini M, Bernini SK, Chiodini G, Corsini A, Ferri N, Fumagalli L, Straniero V, Valoti E.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5408-12. doi: 10.1016/j.bmcl.2011.07.003. Epub 2011 Jul 13.

PMID:
21802946
44.

New Ras CAAX mimetics: design, synthesis, antiproliferative activity, and RAS prenylation inhibition.

Bolchi C, Pallavicini M, Fumagalli L, Ferri N, Corsini A, Rusconi C, Valoti E.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5500-4. doi: 10.1016/j.bmcl.2009.07.065. Epub 2009 Jul 17.

PMID:
19666221
45.

An investigation into the influence of counterion on the RS-propranolol and S-propranolol skin permeability.

Cilurzo F, Minghetti P, Alberti E, Gennari CG, Pallavicini M, Valoti E, Montanari L.

J Pharm Sci. 2010 Mar;99(3):1217-24. doi: 10.1002/jps.21891.

PMID:
19653283
46.

5-(2-Pyrrolidinyl)oxazolidinones and 2-(2-pyrrolidinyl)benzodioxanes: synthesis of all the stereoisomers and alpha4beta2 nicotinic affinity.

Pallavicini M, Bolchi C, Binda M, Cilia A, Clementi F, Ferrara R, Fumagalli L, Gotti C, Moretti M, Pedretti A, Vistoli G, Valoti E.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):854-9. doi: 10.1016/j.bmcl.2008.12.002. Epub 2008 Dec 6.

PMID:
19097783
47.

[Reactive anxiety crisis: a unique case of work injury].

Taino G, Gazzoldi T, Marandola P, Valoti E, Fabris F, Imbriani M.

G Ital Med Lav Ergon. 2007 Jul-Sep;29(3 Suppl):630-1. Italian.

PMID:
18409875
48.

Modelling of full-length human alpha4beta2 nicotinic receptor by fragmental approach and analysis of its binding modes.

Pedretti A, Marconi C, Bolchi C, Fumagalli L, Ferrara R, Pallavicini M, Valoti E, Vistoli G.

Biochem Biophys Res Commun. 2008 May 2;369(2):648-53. doi: 10.1016/j.bbrc.2008.02.080. Epub 2008 Feb 25.

PMID:
18302933
49.

Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency.

Bolchi C, Pallavicini M, Rusconi C, Diomede L, Ferri N, Corsini A, Fumagalli L, Pedretti A, Vistoli G, Valoti E.

Bioorg Med Chem Lett. 2007 Nov 15;17(22):6192-6. Epub 2007 Sep 8.

PMID:
17889533
50.

WB4101-related compounds: new, subtype-selective alpha1-adrenoreceptor antagonists (or inverse agonists?).

Pallavicini M, Budriesi R, Fumagalli L, Ioan P, Chiarini A, Bolchi C, Ugenti MP, Colleoni S, Gobbi M, Valoti E.

J Med Chem. 2006 Nov 30;49(24):7140-9.

PMID:
17125266

Supplemental Content

Loading ...
Support Center